Key facts
- Tangji Medical’s last known valuation is $185.4M (Nov 2025).
- It has raised $44.0M; the latest was IPO in Feb 2026.
- Notable investors include Baidu Ventures, Proxima Ventures (China), Hangzhou Hi-Tech Financial Investment Group, Wuxi Guolian Development (Group), Guanghua Kaiyuan Capital — 18 tracked in total.
- Status: In IPO Registration.
Investors
18+- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Tangji Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Tangji Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tangji Medical
Development and manufacturer of stent medical devices designed for the treatment of metabolic diseases. The company's main products include gastric bypass stent system and related stent devices, enabling patients to be relieved from metabolic diseases.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2016
- Employees
- 128
- Website
- tangjimed.com/
- Ownership
- In IPO Registration
Tangji Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tangji Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tangji Medical in its N-PORT filings yet. We sweep new filings monthly.